David Roman
Stock Analyst at Goldman Sachs
(1.98)
# 3,042
Out of 5,180 analysts
66
Total ratings
39.47%
Success rate
-5.93%
Average return
Main Sectors:
Stocks Rated by David Roman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $98 → $93 | $62.93 | +47.78% | 2 | Mar 27, 2026 | |
| PODD Insulet | Maintains: Buy | $363 → $326 | $208.01 | +56.72% | 2 | Feb 19, 2026 | |
| BAX Baxter International | Maintains: Neutral | $21 → $17 | $15.80 | +7.59% | 5 | Feb 17, 2026 | |
| EW Edwards Lifesciences | Maintains: Buy | $108 → $95 | $79.50 | +19.50% | 5 | Feb 11, 2026 | |
| DOCS Doximity | Maintains: Neutral | $46 → $34 | $23.73 | +43.28% | 5 | Feb 9, 2026 | |
| MDLN Medline | Initiates: Buy | $49 | $42.62 | +14.97% | 1 | Jan 12, 2026 | |
| HQY HealthEquity | Downgrades: Sell | $89 | $81.48 | +9.23% | 4 | Jan 9, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Neutral | $22 → $25 | $18.33 | +36.39% | 3 | Dec 15, 2025 | |
| COO The Cooper Companies | Maintains: Sell | $64 → $71 | $69.31 | +2.44% | 2 | Dec 8, 2025 | |
| MDT Medtronic | Upgrades: Neutral | $81 → $111 | $85.74 | +29.46% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $202 | $114.21 | +76.87% | 4 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $33 | $9.86 | +234.69% | 3 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $15.26 | +4.85% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $103 | $105.01 | -1.91% | 1 | Oct 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $14.19 | +40.94% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $9.23 | +105.85% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $12.05 | +140.76% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $104 | $88.62 | +17.36% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $5.14 | +94.55% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $94 → $82 | $68.77 | +19.24% | 3 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $138 → $154 | $101.88 | +51.16% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $24 | $19.59 | +22.54% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $63 → $71 | $63.45 | +11.90% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $55 | $61.27 | -10.23% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $384 → $427 | $326.10 | +30.94% | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $500 | $452.78 | +10.43% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $274 | $154.69 | +77.13% | 1 | May 30, 2024 |
Boston Scientific
Mar 27, 2026
Maintains: Buy
Price Target: $98 → $93
Current: $62.93
Upside: +47.78%
Insulet
Feb 19, 2026
Maintains: Buy
Price Target: $363 → $326
Current: $208.01
Upside: +56.72%
Baxter International
Feb 17, 2026
Maintains: Neutral
Price Target: $21 → $17
Current: $15.80
Upside: +7.59%
Edwards Lifesciences
Feb 11, 2026
Maintains: Buy
Price Target: $108 → $95
Current: $79.50
Upside: +19.50%
Doximity
Feb 9, 2026
Maintains: Neutral
Price Target: $46 → $34
Current: $23.73
Upside: +43.28%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $49
Current: $42.62
Upside: +14.97%
HealthEquity
Jan 9, 2026
Downgrades: Sell
Price Target: $89
Current: $81.48
Upside: +9.23%
Kestra Medical Technologies
Dec 15, 2025
Maintains: Neutral
Price Target: $22 → $25
Current: $18.33
Upside: +36.39%
The Cooper Companies
Dec 8, 2025
Maintains: Sell
Price Target: $64 → $71
Current: $69.31
Upside: +2.44%
Medtronic
Nov 19, 2025
Upgrades: Neutral
Price Target: $81 → $111
Current: $85.74
Upside: +29.46%
Oct 31, 2025
Maintains: Neutral
Price Target: $180 → $202
Current: $114.21
Upside: +76.87%
Oct 29, 2025
Maintains: Buy
Price Target: $26 → $33
Current: $9.86
Upside: +234.69%
Oct 1, 2025
Initiates: Neutral
Price Target: $16
Current: $15.26
Upside: +4.85%
Oct 1, 2025
Initiates: Buy
Price Target: $103
Current: $105.01
Upside: -1.91%
Aug 25, 2025
Initiates: Buy
Price Target: $20
Current: $14.19
Upside: +40.94%
Aug 18, 2025
Initiates: Buy
Price Target: $19
Current: $9.23
Upside: +105.85%
Jul 1, 2025
Initiates: Buy
Price Target: $29
Current: $12.05
Upside: +140.76%
May 6, 2025
Maintains: Neutral
Price Target: $120 → $104
Current: $88.62
Upside: +17.36%
May 1, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $5.14
Upside: +94.55%
May 1, 2025
Maintains: Buy
Price Target: $94 → $82
Current: $68.77
Upside: +19.24%
Mar 4, 2025
Maintains: Buy
Price Target: $138 → $154
Current: $101.88
Upside: +51.16%
Mar 3, 2025
Maintains: Neutral
Price Target: $42 → $24
Current: $19.59
Upside: +22.54%
Mar 3, 2025
Maintains: Sell
Price Target: $63 → $71
Current: $63.45
Upside: +11.90%
Mar 3, 2025
Maintains: Buy
Price Target: $64 → $55
Current: $61.27
Upside: -10.23%
Jan 30, 2025
Maintains: Neutral
Price Target: $384 → $427
Current: $326.10
Upside: +30.94%
May 30, 2024
Initiates: Buy
Price Target: $500
Current: $452.78
Upside: +10.43%
May 30, 2024
Initiates: Buy
Price Target: $274
Current: $154.69
Upside: +77.13%